Antibodies That Bind Both IL-17A and IL-17F and Methods of Using the Same
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 12 of these applications claim priority to application 11/684,907, filed Mar 12, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 7,910,703 | Antagonists to IL-17A, IL-17F, and IL-23P19 and Methods of Use In force · High confidence | ZymoGenetics, Inc. | In force | High confidence | ||
| US 8,871,467 | Polynucleotides Encoding Antibodies That Bind Both IL-17A and IL-17F In force · Low confidence | ZymoGenetics, Inc. | In force | Low confidence | ||
| US 8,992,922 | Antagonists of IL-17A, IL-17F, and IL-23P19 In force · Medium confidence | ZymoGenetics, Inc. | In force | Medium confidence | ||
| US 9,416,183 | Methods of Treating Inflammatory Diseases Using Antibodies That Bind Both IL-17A and IL-17F In force · Medium confidence | ZymoGenetics, Inc. | In force | Medium confidence | ||
| US 9,464,134 | Polynucleotides Encoding Antagonists of IL-17A, IL-17F, and IL-23P19 In force · Medium confidence | ZymoGenetics, Inc. | In force | Medium confidence | ||
| US 9,663,572 | Antibodies That Bind Both IL-17A and IL-17F In force · Medium confidence | ZymoGenetics, Inc. | In force | Medium confidence | ||
| US 9,994,634 | Use of an IL-17/IL-23 Bispecific Antibody for Treating Inflammation In force · Medium confidence | ZymoGenetics, Inc. | In force | Medium confidence | ||
| US 10,000,563 | Monoclonal Antibodies That Bind Both IL-17A and IL-17F In force · Medium confidence | ZymoGenetics, Inc. | In force | Medium confidence | ||
| US 10,023,656 | Methods of Treating Inflammation Using IL-17A and IL-17F Cross-Reactive Monoclonal Antibodies In force · Low confidence | ZymoGenetics, Inc. | In force | Low confidence | ||
| US 10,562,967 | Treating Inflammation with IL-17/IL-23 Bispecific Antibodies In force · Medium confidence | ZymoGenetics, Inc. | In force | Medium confidence | ||
| 6 more patents in this group · Pro | ||||||
10 of 16 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 16, including 13 expiring within the 18 months from Nov 15, 2026.
13 of these are in force and held by ZymoGenetics Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.